Traditionally, hospitals had little financial incentive to improve quality of care. They were paid based on the number of infections treated – even if mistakes occurred or those infections were preventable. With today’s healthcare system moving toward outcomes-based reimbursement, healthcare organizations are being held accountable for hospital-associated infection (HAI) rates.
As CMS and even private payment systems become more active payers of high-quality healthcare services, hospitals are adopting broader, vigilant infection-control strategies to prevent HAIs. A large part of these strategies include the use of antimicrobial-treated medical devices and surfaces to limit patient exposure to dangerous microorganisms.
Sciessent’s Agion line of antimicrobial technology is embedded in numerous FDA-approved medical devices and surfaces. With clinical data to prove its efficacy, Sciessent’s technology works on the surface of products to attack microbes and inhibit their growth – acting as second line of defense in the war against HAIs.